Browsing by Author "Gupta K."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    ItemMetadata only
    Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study
    (2023-06-01) Medas F.; Dobrinja C.; Al-Suhaimi E.A.; Altmeier J.; Anajar S.; Arikan A.E.; Azaryan I.; Bains L.; Basili G.; Bolukbasi H.; Bononi M.; Borumandi F.; Bozan M.B.; Brenta G.; Brunaud L.; Brunner M.; Buemi A.; Canu G.L.; Cappellacci F.; Cartwright S.B.; Castells Fusté I.; Cavalheiro B.; Cavallaro G.; Chala A.; Chan S.Y.B.; Chaplin J.; Cheema M.S.; Chiapponi C.; Chiofalo M.G.; Chrysos E.; D'Amore A.; de Cillia M.; De Crea C.; de Manzini N.; de Matos L.L.; De Pasquale L.; Del Rio P.; Demarchi M.S.; Dhiwakar M.; Donatini G.; Dora J.M.; D'Orazi V.; Doulatram Gamgaram V.K.; Eismontas V.; Kabiri E.H.; El Malki H.O.; Elzahaby I.; Enciu O.; Eskander A.; Feroci F.; Figueroa-Bohorquez D.; Filis D.; François G.; Frías-Fernández P.; Gamboa-Dominguez A.; Genc V.; Giordano D.; Gómez-Pedraza A.; Graceffa G.; Griffin J.; Guerreiro S.C.; Gupta K.; Gupta K.K.; Gurrado A.; Hajiioannou J.; Hakala T.; Harahap W.A.; Hargitai L.; Hartl D.; Hellmann A.; Hlozek J.; Hoang V.T.; Iacobone M.; Innaro N.; Ioannidis O.; Jang J.H.I.; Xavier-Junior J.C.; Jovanovic M.; Kaderli R.M.; Kakamad F.; Kaliszewski K.; Karamanliev M.; Katoh H.; Košec A.; Kovacevic B.; Kowalski L.P.; Králik R.; Yadav S.K.; Kumorová A.; Lampridis S.; Lasithiotakis K.; Leclere J.C.; Leong E.K.F.; Leow M.K.S.; Lim J.Y.; Lino-Silva L.S.; Liu S.Y.W.; Llorach N.P.; Lombardi C.P.; López-Gómez J.; Mahidol University
    BACKGROUND: Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading to diagnosis and treatment delays, with an increased number of neoplasms at advanced stages worldwide. The aims of this study were to quantify the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic; and to evaluate whether delays in surgery led to an increased occurrence of aggressive tumours. METHODS: In this retrospective, international, cross-sectional study, centres were invited to participate in June 22, 2022; each centre joining the study was asked to provide data from medical records on all surgical thyroidectomies consecutively performed from Jan 1, 2019, to Dec 31, 2021. Patients with indeterminate thyroid nodules were divided into three groups according to when they underwent surgery: from Jan 1, 2019, to Feb 29, 2020 (global prepandemic phase), from March 1, 2020, to May 31, 2021 (pandemic escalation phase), and from June 1 to Dec 31, 2021 (pandemic decrease phase). The main outcomes were, for each phase, the number of surgeries for indeterminate thyroid nodules, and in patients with a postoperative diagnosis of thyroid cancers, the occurrence of tumours larger than 10 mm, extrathyroidal extension, lymph node metastases, vascular invasion, distant metastases, and tumours at high risk of structural disease recurrence. Univariate analysis was used to compare the probability of aggressive thyroid features between the first and third study phases. The study was registered on ClinicalTrials.gov, NCT05178186. FINDINGS: Data from 157 centres (n=49 countries) on 87 467 patients who underwent surgery for benign and malignant thyroid disease were collected, of whom 22 974 patients (18 052 [78·6%] female patients and 4922 [21·4%] male patients) received surgery for indeterminate thyroid nodules. We observed a significant reduction in surgery for indeterminate thyroid nodules during the pandemic escalation phase (median monthly surgeries per centre, 1·4 [IQR 0·6-3·4]) compared with the prepandemic phase (2·0 [0·9-3·7]; p<0·0001) and pandemic decrease phase (2·3 [1·0-5·0]; p<0·0001). Compared with the prepandemic phase, in the pandemic decrease phase we observed an increased occurrence of thyroid tumours larger than 10 mm (2554 [69·0%] of 3704 vs 1515 [71·5%] of 2119; OR 1·1 [95% CI 1·0-1·3]; p=0·042), lymph node metastases (343 [9·3%] vs 264 [12·5%]; OR 1·4 [1·2-1·7]; p=0·0001), and tumours at high risk of structural disease recurrence (203 [5·7%] of 3584 vs 155 [7·7%] of 2006; OR 1·4 [1·1-1·7]; p=0·0039). INTERPRETATION: Our study suggests that the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic period could have led to an increased occurrence of aggressive thyroid tumours. However, other compelling hypotheses, including increased selection of patients with aggressive malignancies during this period, should be considered. We suggest that surgery for indeterminate thyroid nodules should no longer be postponed even in future instances of pandemic escalation.None.
  • No Thumbnail Available
    ItemMetadata only
    The AOFOG recommendations on human papillomavirus vaccination in the Asia-Pacific region
    (2024-10-01) Tse K.Y.; Tan A.L.; Subedi K.; Pervin S.; Gupta K.; Tjokroprawiro B.A.; Woo Y.L.; Wilailak S.; Ochiai K.; Lumbiganon P.; Padolina C.; Tse K.Y.; Mahidol University
    Cervical cancer remains a disease burden in Asia. The Asia and Oceania Federation of Obstetrics and Gynecology envisages a need to produce a set of recommendations on the implementation of human papilloma virus vaccination program for both lower-middle-income countries (LMICs) and high-income countries (HICs), with an attempt to harmonize the practices yet allow flexibility to cater for different cultures, religions, needs and background of individual countries/cities. International guidelines and literature were sought, and recommendations were made in seven selected areas, including (i) the target groups for vaccination, (ii) the doses of vaccination including the use of single-dose vaccination, (iii) the types of vaccines, (iv) suggestions for special populations including those with previous HPV infection, human immunodeficiency virus carriers, and lesbian, gay, bisexual, transgender, questioning/queer group, (v) inter-changeability and the need of revaccination/booster, (vi) novel technologies and vaccines, and (vii) public education.